Image For Activity Cover
Safety/Efficacy of DOAC Versus Aspirin for Reduction of Risk of Cerebrovascular Events Following VT Ablation - JCEP December 2021
Safety/Efficacy of DOAC Versus Aspirin for Reduction of Risk of Cerebrovascular Events Following VT Ablation - JCEP December 2021
The STROKE-VT is a multicenter, randomized controlled trial that studied the differences in cerebrovascular events (CVE) between direct oral anticoagulant (DOAC) vs. ASA use post-procedurally in patients undergoing left ventricular arrhythmia (LVA) ablation [ventricular tachycardia (VT) or premature ventricular contraction (PVC)] using radiofrequency ablation (RFA). DOAC utilization following endocardial/epicardial ablation for LVA-RFA was associated with reduced risk of transient ischemic attack or stroke, and asymptomatic MRI-detected cerebrovascular event.


Editor-in-Chief
Kalyanam Shivkumar, MD, PhD, FACC 

CME Editor
Kenneth A. Ellenbogen, MD

Author
Kenneth A. Ellenbogen, MD

Important Dates
Date of Release: December 20, 2021   
Term of Approval/Date of CME/MOC/ECME Expiration: December 19, 2022
Summary
Availability: On-Demand
Expires on Dec 19, 2022
Cost: FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
1 ECME Credit
Android App Download IOS App Download Powered By